过去一年中添加的文章,按日期排序

Abstract LB220: Farnesyltransferase inhibitors show synergistic anticancer effects in combination with novel KRAS G12C inhibitors

J Timar, M Baranyi, E Molnar, I Randelovic… - Cancer Research, 2024 - AACR
121 天前 - … immunotherapy as well as SOS- and SHP2-inhibitors. Based on in-silico analysis
of … compensatory re-activation of HRAS, farnesylation of RHEB in the PI3K/mTOR pathway

Non-genetic determinants driving the evolutional trajectories of drug-tolerant-persisters in KRAS Non-small cell lung cancer

C Li, CJ Graser, Q Qin, A Nimbalkar, U Syed… - Cancer Research, 2024 - AACR
135 天前 - inhibitors with drugs that target mitogen-activated protein kinase (MAPK) feedback
reactivation… to therapies targeting different pathways, eg, KRAS+ SHP2, KRAS+CDK4/6, and …

53P PHI-501 as a potent pan-RAF/DDRs inhibitor suppresses colorectal cancer cell proliferation and overcomes BRAF inhibitor resistance

SM Kim, GJ Sung, S Cho, JH Han, KY Nam, KT Kim… - ESMO Open, 2024 - esmoopen.com
185 天前 - … that PHI-501 inhibited the phosphorylation of MEK, ERK, AKT, and SHP2 proteins in
the … that PHI-501 considerably suppressed the reactivation of pERK and pAKT. In BRAF- or …

Combining RASG12C(ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a strategy for turning cold …

P Anastasiou, C Moore, S Rana, A de Castro… - bioRxiv, 2024 - biorxiv.org
201 天前 - reactivation of upstream RTKs which can result in the activation of wild-type and
mutant … we provide evidence that suggests direct effects of SHP2 inhibitor on cells of the TME. …

JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers

X Lu, R Yu, Z Li, M Yang, J Dai, M Liu - Cancer Letters, 2024 - Elsevier
235 天前 - reactivated ERK upon treatment for 12 h in A549 cells, and SHP2 inhibition by JC-010a
prevented the reactivation … signaling pathways were due to its inhibition effect on SHP2. …

Abstract C141: Targeting SHP2-dependent adaptive resistance to BRAF and MEK inhibition in gliomas

AA Ayanlaja, K Lalwani, M Ioannou, C Pratilas… - Molecular Cancer …, 2023 - AACR
247 天前 - … role of SHP2 upstream of RAS pathway, we postulated that the combination of SHP2i
and BRAFi/MEKi would maintain superior ERK pathway inhibition in … ERK reactivation and …

SHP2 Inhibition Overcomes Adaptive and Acquired Resistance to FLT3 TKI to Improve Efficacy Against FLT3/ITD AML

T Seale, L Li, JK Bruner, B Nguyen, MJ Levis… - Blood, 2023 - Elsevier
250 天前 - … the activation of the ERK pathway. Therefore, we explored … SHP2 inhibitor decreases
the adaptive ERK reactivation … to the versatile efficacy of SHP2 inhibition in multiple AML …

870 CoREST inhibition by TNG260 increases expression of immunomodulatory genes in STK11-mutant cancer and sensitizes to immune checkpoint blockade

L Ahronian, M Zhang, P Shahagadkar, A Bejnood… - 2023 - jitc.bmj.com
277 天前 - … (ON) inhibitor RM-029 still resulted in RAS pathway reactivation. … pathway. In an
inflamed, anti-PD-1 sensitive mouse model of NSCLC, KRAS G12C (ON) and SHP2 inhibitors

[HTML][HTML] 871 Combining KRASG12C (ON) inhibitor with SHP2 and/or immune checkpoint blockade to overcome adaptive resistance and enhance anti-tumour …

P Anastasiou, C Moore, S Rana, J Boumelha… - 2023 - jitc.bmj.com
277 天前 - … of cell viability than the KRAS G12C (OFF) inhibitor MRTX849 in both … ) inhibitor
RM-029 still resulted in RAS pathway reactivation. Addition of RMC-4550 blocked RAS pathway

Unravelling Resistance Mechanisms in Philadelphia Positive Leukemias: Targeted Treatment Strategies to Overcome Resistance

G Poudel - 2023 - digital.library.adelaide.edu.au
285 天前 - … on BCR::ABL1 reactivation, the mechanisms of … inhibit this pathway by blocking
BCR::ABL1 and inducing apoptosis in CML cells. However, the activation of the RAS pathway